Emerging Anticoagulant Drugs

Abstract—The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.

[1]  A. Greinacher,et al.  Recombinant Hirudin in Clinical Practice: Focus on Lepirudin , 2001, Circulation.

[2]  K. Wegscheider,et al.  Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. , 1999, Journal of the American College of Cardiology.

[3]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[4]  E. Antman.  Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. , 1994, Circulation.

[5]  F. Van de Werf,et al.  Argatroban and Alteplase in Patients with Acute Myocardial Infarction: The ARGAMI Study , 2000, Journal of Thrombosis and Thrombolysis.

[6]  Ulf Bredberg,et al.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.

[7]  S. Yamamoto,et al.  Effects of Recombinant Human Soluble Thrombomodulin (rhs-TM) on a Rat Model of Disseminated Intravascular Coagulation with Decreased Levels of Plasma Antithrombin III , 1994, Thrombosis and Haemostasis.

[8]  MassimoChiariello,et al.  Antithrombotic Effects of Recombinant Human, Active Site–Blocked Factor VIIa in a Rabbit Model of Recurrent Arterial Thrombosis , 1998 .

[9]  A. Chang,et al.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. , 1993, The Journal of clinical investigation.

[10]  D. Waters,et al.  Pathophysiology and initial management of the acute coronary syndromes. , 1996, Current opinion in cardiology.

[11]  A. Mattioli,et al.  Organization to Assess Strategies for Ischemic Syndrome (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST eleva , 1999 .

[12]  J. Miletich,et al.  Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. , 1990, Science.

[13]  B. Eriksson,et al.  Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement* , 1997, The Journal of bone and joint surgery. American volume.

[14]  F. Van de Werf,et al.  A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. , 2001, European heart journal.

[15]  C. Vlahos,et al.  Stable expression of a secretable deletion mutant of recombinant human thrombomodulin in mammalian cells. , 1990, The Journal of biological chemistry.

[16]  S. Bajaj,et al.  Tissue Factor Pathway Inhibitor: Potential Therapeutic Applications , 1997, Thrombosis and Haemostasis.

[17]  M. Simoons.  A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.

[18]  S. Rapaport,et al.  A monoclonal antibody to factor IX that inhibits the factor VIII:Ca potentiation of factor X activation. , 1985, The Journal of biological chemistry.

[19]  K. E. Sanders,et al.  Intersubunit circular permutation of human hemoglobin. , 2002, Blood.

[20]  P. Meda,et al.  Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. , 2002, Blood.

[21]  U. Tebbe,et al.  Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) , 1994, Circulation.

[22]  C. Dunwiddie,et al.  Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. , 1994, Circulation.

[23]  J. Herbert,et al.  Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. , 1998, Blood.

[24]  J. Maraganore,et al.  Thrombin-specific inhibition by and slow cleavage of hirulog-1. , 1992, The Biochemical journal.

[25]  K. Nakagawa,et al.  Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model. , 1996, American journal of clinical pathology.

[26]  H. Rupprecht,et al.  Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. , 1996, European heart journal.

[27]  K. Hajjar,et al.  A mediator of cell surface-specific plasmin generation. , 2006, Annals of the New York Academy of Sciences.

[28]  C. Esmon,et al.  Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. , 1982, The Journal of biological chemistry.

[29]  M. Samama,et al.  Absence of In Vitro Cross-Reaction of Pentasaccharide with the Plasma Heparin-Dependent Factor of Twenty-Five Patients with Heparin-Associated Thrombocytopenia , 1995, Thrombosis and Haemostasis.

[30]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[31]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[32]  U. Hedner,et al.  Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. , 1997, Journal of vascular surgery.

[33]  A A Connolly,et al.  Deep vein thrombosis. , 1988, BMJ.

[34]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[35]  D. Fitzgerald,et al.  Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. , 1996, Coronary artery disease.

[36]  C. Francis,et al.  Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.

[37]  A. Greinacher,et al.  Monitoring of r-Hirudin Anticoagulation during Cardiopulmonary Bypass – Assessment of the Whole Blood Ecarin Clotting Time , 1997, Thrombosis and Haemostasis.

[38]  J. Maraganore,et al.  Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.

[39]  M. Samama,et al.  Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. , 1997, Thrombosis research.

[40]  C. Esmon,et al.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Yamamoto,et al.  Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. , 1990, Blood.

[42]  B. Eriksson,et al.  Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial , 2002, The Lancet.

[43]  P. Rolan,et al.  Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin , 1997, Clinical pharmacology and therapeutics.

[44]  C. Esmon,et al.  Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. , 1997, Circulation.

[45]  V. Fuster.  Elucidation off the role of plaque instability and rupture in acute coronary events , 1995 .

[46]  T. Lyle,et al.  Small-molecule inhibitors of thrombin , 1994 .

[47]  C. E. Ettingshausen,et al.  Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans , 1999, Seminars in thrombosis and hemostasis.

[48]  J. Oliver,et al.  Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. , 1995, Blood.

[49]  J. Ferguson.  Meeting Highlights American Heart Association Scientific Sessions 2001 , 2002 .

[50]  J. Herbert,et al.  DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[51]  J. Labarca,et al.  Heparin-induced transaminase elevations: a prospective study. , 1993, International journal of clinical pharmacology, therapy, and toxicology.

[52]  V. Fuster.  Elucidation of the role of plaque instability and rupture in acute coronary events. , 1995, The American journal of cardiology.

[53]  Bridget Wilcken,et al.  Pathogenesis of coronary artery disease , 1969 .

[54]  J. A. Bittl,et al.  Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. , 1995, American heart journal.

[55]  E. Antman.  Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.

[56]  K. Fox.  Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. , 1999, The American journal of cardiology.

[57]  B. Eriksson,et al.  O1067 INFLUENCE OF THE DURATION OF FONDAPARINUX PROPHYLAXIS IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY , 2004 .

[58]  S. Hanson,et al.  Antithrombotic Strategies Targeting Thrombin Activities, Thrombin Receptors and Thrombin Generation , 1997, Thrombosis and Haemostasis.

[59]  H. Büller,et al.  Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. , 1996, Circulation.

[60]  L. Wilkins.  Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.

[61]  P. Petersen,et al.  Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation , 2003 .

[62]  V. Hasselblad,et al.  First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation , 2002, Circulation.

[63]  G. Raskob,et al.  Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.

[64]  I. Maruyama.  Recombinant Thrombomodulin and Activated Protein C in the Treatment of Disseminated Intravascular Coagulation , 1999, Thrombosis and Haemostasis.

[65]  K. Brune,et al.  Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet , 2002, Clinical pharmacology and therapeutics.

[66]  P. Lollar,et al.  Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation. , 1984, The Journal of biological chemistry.

[67]  B. Eriksson,et al.  Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. , 2002, Archives of internal medicine.

[68]  K. Stringer,et al.  Hirudins: Antithrombin Anticoagulants , 1992, The Annals of pharmacotherapy.

[69]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[70]  J. Maraganore,et al.  Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans , 1993, Thrombosis and Haemostasis.

[71]  V. Fuster,et al.  Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. , 1998, Journal of the American College of Cardiology.

[72]  R. Huber,et al.  The structure of a complex of recombinant hirudin and human alpha-thrombin. , 1990, Science.

[73]  Y. Terada,et al.  Tolerability, pharmacokinetics, and pharmacodynamics of DX‐9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers , 1999, Clinical pharmacology and therapeutics.

[74]  M. Pfisterer,et al.  Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospective Study , 1996, Thrombosis and Haemostasis.

[75]  J. Necciari,et al.  Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man , 1995, Thrombosis and Haemostasis.

[76]  G. Feuerstein,et al.  An Inhibitory Anti-factor IX Antibody Effectively Reduces Thrombus Formation in a Rat Model of Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[77]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[78]  A. Marcus,et al.  Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. , 1998, The Journal of clinical investigation.

[79]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[80]  P. Petersen,et al.  Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. , 2003, Journal of the American College of Cardiology.

[81]  Eter,et al.  A COMPARISON OF RECOMBINANT HIRUDIN WITH A LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT THROMBOEMBOLIC COMPLICATIONS AFTER TOTAL HIP REPLACEMENT , 2000 .

[82]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[83]  D. Hommes,et al.  Monitoring Anticoagulant Therapy by Activated Partial Thromboplastin Time: Hirudin Assessment , 1994, Thrombosis and Haemostasis.

[84]  Claude,et al.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. , 1991, The Journal of clinical investigation.

[85]  R. Postier,et al.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study , 2001, Critical care medicine.

[86]  R. Peters,et al.  Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers , 2002, Circulation.

[87]  J. Herbert,et al.  Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[88]  S. Schulman,et al.  A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.

[89]  E. Topol,et al.  Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. , 1995, Circulation.

[90]  D. Banner,et al.  Inhibitor binding to thrombin: x-ray crystallographic studies. , 1993, Advances in experimental medicine and biology.

[91]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[92]  C. Dunwiddie,et al.  Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. , 1989, The Journal of biological chemistry.

[93]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[94]  R. Colman,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 1988 .

[95]  C. Esmon,et al.  Thrombomodulin blocks the ability of thrombin to activate platelets. , 1983, The Journal of biological chemistry.

[96]  Steven H. Huang,et al.  Anticoagulant repertoire of the hookworm Ancylostoma caninum. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[97]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[98]  V. Hasselblad,et al.  Clinical outcomes of bivalirudin for ischemic heart disease. , 1999, Circulation.

[99]  J. Hofsteenge,et al.  The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudin. , 1990, European journal of biochemistry.

[100]  G. Vlasuk.  Structural and Functional Characterization of Tick Anticoagulant Peptide (TAP): A Potent and Selective Inhibitor of Blood Coagulation Factor Xa , 1993, Thrombosis and Haemostasis.

[101]  E. Topol,et al.  Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). , 2002, American heart journal.

[102]  Mary L. Westbrook,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991 .

[103]  G. Tuszynski,et al.  Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. , 1987, The Journal of biological chemistry.

[104]  D. Diuguid.  Choosing a parenteral anticoagulant agent. , 2001, The New England journal of medicine.

[105]  J. Maraganore,et al.  HIRUDIN INTERACTIONS WITH THROMBIN , 1992 .

[106]  E. Davie.  Biochemical and Molecular Aspects of the Coagulation Cascade , 1995, Thrombosis and Haemostasis.

[107]  Organisation to Assess Strategies for Ischemic Syndromes Investigators.  Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial , 1999, The Lancet.

[108]  Kenneth J. Alford,et al.  Novastan® (Brand of Argatroban): A Small-Molecule, Direct Thrombin Inhibitor , 1997, Seminars in thrombosis and hemostasis.

[109]  G. Feuerstein,et al.  Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[110]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[111]  L. Johansson,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[112]  J. Miletich,et al.  Importance of factor Xa in determining the procoagulant activity of whole-blood clots. , 1993, The Journal of clinical investigation.

[113]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. , 2001, The New England journal of medicine.

[114]  K. Sakariassen,et al.  Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[115]  E. Alderman.  Results from late-breaking clinical trials sessions at ACC '98. American College of Cardiology. , 1998, Journal of the American College of Cardiology.

[116]  R. Califf,et al.  Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data , 2002, The Lancet.

[117]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.

[118]  A. Tulinsky,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991, Journal of molecular biology.

[119]  C. Colwell,et al.  Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. , 2001, Archives of internal medicine.

[120]  B. Eriksson,et al.  Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement , 2003, Thrombosis and Haemostasis.

[121]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[122]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[123]  S. Swan,et al.  The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction , 2000, Pharmacotherapy.

[124]  R. Sinden,et al.  Chromosomes in living Escherichia coli cells are segregated into domains of supercoiling. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[125]  E. Topol,et al.  Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. , 2001, American heart journal.